Ergosterol

Ergosterol: A Comprehensive Reference

1. Identity, Chemistry, and Physical Properties

Ergosterol (ergosta-5,7,22-trien-3β-ol) is a sterol found in fungi, named after ergot, the common name of members of the fungal genus Claviceps from which ergosterol was first isolated. Its full systematic chemical name is (24R)-ergosta-5,7,22-trien-3β-ol, and it is also formally denoted as 24R-methyl-cholesta-5,7,22(E)-trienol. Ergosterol is the main mycosterol found in cell membranes of fungi, yeasts, and protozoa.

Ergosterol was first discovered in 1889, in the plant pathogenic ergot fungus Claviceps purpurea. It is an analog of cholesterol present in mammalian cell membranes. Structurally, ergosterol closely resembles cholesterol, differing only in side-chain composition and degree of unsaturation.

Ergosterol is a steroidal compound that forms colorless acicular or flaky crystals with the molecular formula C₂₈H₄₄O. It exhibits solubility in ethanol, ether, benzene, and trichloromethane, and remains insoluble in water. Poor aqueous solubility, physicochemical instability, and low oral bioavailability are characteristics that significantly affect its use as a dietary supplement or pharmaceutical agent.

Sterols are essential lipids of most eukaryotic cells, ensuring important structural and signaling functions. Like cholesterol, ergosterol and other mycosterols play similar roles in the permeability and fluidity of fungal cell membranes. Ergosterol, through its protective role against mechanical and oxidative stress, might have been selected by the pressure induced by drying/wetting cycles occurring in the fungi habitats.

2. Natural Sources and Distribution

Triterpene ergosterol is the main sterol identified in cell membranes of fungi. Ergosterol is also present in the cell membranes of some protists, such as trypanosomes. However, since ergosterol was discovered over 100 years ago in the plant pathogenic ergot fungus Claviceps purpurea, it has been considered to be the "fungal sterol," although ergosterol is not present in all fungi — the misconception came about because most of the first fungi analyzed for sterols were among later diverging species (Ascomycota and Basidiomycota).

Commercially, ergosterol is obtained in notable concentrations from edible and medicinal mushrooms. Agaricus bisporus mushrooms contain high levels of ergosterol (3–8 mg/g dry weight), which can be converted into vitamin D₂ under ultraviolet irradiation. Among a broad survey of dried commercial mushrooms, the average ergosterol content was 1.98 mg/g, while the average vitamin D₂ content was 16.88 µg/g.

All edible mushrooms are high in ergosterol. Mushrooms have historically been used as medicines and tonics, with Lentinula edodes (shiitake), Grifola frondosa (maitake), Ganoderma lucidum (reishi), Cordyceps sinensis, and Hericium erinaceus being used in traditional Chinese medicine formulations.

Fungi are grown industrially to enable ergosterol extraction and preparation as a powder for sale as a vitamin D₂ dietary supplement and food additive. Common species used for industrial ergosterol production include Saccharomyces cerevisiae (baker's/brewer's yeast) and various Basidiomycete mushroom species.

3. Common Forms and Preparations

• Crude mushroom powder or whole dried mushroom: Dried commercial mushrooms have higher contents of ergosterol and vitamin D₂ than fresh mushrooms.
• UV-irradiated mushroom preparations: Exposure of white button mushrooms to UV-C irradiation produces time-dependent increases in vitamin D₂ concentrations in the mushrooms. Preparations of irradiated ergosterol containing a mixture of previtamin and vitamin D₂ were called viosterol in the 1930s.
• Ergosterol as provitamin D₂ supplement: To make vitamin D₂, ergosterol is dissolved in chloroform, ether, cyclohexane, or other solvents and exposed to ultraviolet light. Ergosterol is a precursor to vitamin D₂ and can be used as an intermediate in hormone drugs or to make "cortisone" and "progesterone."
• Purified ergosterol extract: Used in research and increasingly in nutraceutical formulations, typically produced by solvent extraction from fungal biomass.
• Nanoparticle and lipid-based delivery systems: A range of carriers — including liposomes, nanoparticles, microemulsions, micelles, and ferritin cages — has been developed to increase the effective concentration of ergosterol at target sites and enhance its pharmacological effects.

4. Traditional and Historical Use

4.1 Asian Medicinal Traditions

Chinese medicinal mushrooms have a long history of usage in traditional Chinese medicine (TCM) to enhance well-being and treat a range of conditions, including cancer. Ergosterol was not historically isolated and used as a pure compound; rather, it was one of the active constituents inherent in mushroom preparations that had broad traditional uses.

Ganoderma lucidum (lingzhi or reishi), an oriental fungus, has a long history of use for promoting health and longevity in China, Japan, and other Asian countries. In Chinese, the name lingzhi represents a combination of spiritual potency and essence of immortality and is regarded as the "herb of spiritual potency," symbolizing success, well-being, divine power, and longevity. Among cultivated mushrooms, G. lucidum is unique in that its pharmaceutical rather than nutritional value is paramount. Compounds isolated from G. lucidum include ergosterol (provitamin D₂), nucleosides, and nucleotides.

The mushroom Leucocalocybe mongolica has been utilized in traditional Chinese medicine for centuries to fortify the stomach and spleen, and also to bolster immunity. Within traditional Mongolian medicine, L. mongolica is incorporated into mutton soup as a tonic for lactating women, aiming to enhance their immunity and augment maternal milk secretion.

Medicinal mushrooms have been used for centuries in Asian countries owing to their beneficial effects on health and longevity. Shiitake (Lentinus edodes) has been used for thousands of years in East Asian traditional medicine and was cultivated in China as early as the Song Dynasty (960–1279 CE) as a culinary and medicinal food. Lentinus edodes has been shown to have antitumor activity found in lipid fractions, including ergosterol, and has been used for many years to investigate functional properties and to isolate compounds for pharmaceutical use.

Agaricus blazei Murrill (ABM), a mushroom native to Brazil, is popularly known as "Cogumelo do Sol" in Brazil or "Himematsutake" in Japan, and is useful against a variety of diseases like cancer, chronic hepatitis, diabetes, atherosclerosis, and hypercholesterolemia.

4.2 European Historical Context

In Europe, ergosterol's pharmaceutical significance began with its discovery in 1889 and expanded dramatically in the early twentieth century, when the work of Adolph Windaus and Alfred Hess demonstrated that UV irradiation of ergosterol produced a substance capable of preventing rickets. This led to its commercial use as an antirachitic agent — administered as irradiated ergosterol (vitamin D₂, ergocalciferol) — from the 1920s and 1930s onward. Preparations of irradiated ergosterol containing a mixture of previtamin and vitamin D₂ were called viosterol in the 1930s.

5. Key Constituents, Derivatives, and Mechanisms of Action

5.1 Ergosterol as a Structural Membrane Component

Ergosterol is a component of yeast and other fungal cell membranes, serving many of the same functions that cholesterol serves in animal cells. Ergosterol can strengthen the mushroom cell membrane, regulate membrane fluidity, and assist membrane transport, which is similar to cholesterol in animals.

5.2 Ergosterol as a Precursor to Vitamin D₂ (Ergocalciferol)

In human nutrition, ergosterol is a provitamin form of vitamin D₂; exposure to ultraviolet (UV) light causes a chemical reaction that produces vitamin D₂. Ergosterol can be converted to vitamin D₂ under ultraviolet radiation. The photochemical mechanism involves UV-B (290–320 nm) irradiation causing a ring-opening reaction in ergosterol to produce pre-vitamin D₂, which then undergoes thermal isomerization to yield vitamin D₂ (ergocalciferol). The transformation pathway includes previtamin D₂, vitamin D₂, and two byproducts, tachysterol and lumisterol.

5.3 Ergosterol Peroxide and Other Key Derivatives

Each year, hundreds of new metabolites of the main fungal sterol, ergosterol, are isolated from fungal sources, and many of the isolated compounds exhibit one or another biological activity. Among the most pharmacologically significant derivatives are:

• Ergosterol peroxide (5α,8α-epidioxyergosta-6,22-dien-3β-ol): A major oxidized derivative with well-documented anticancer and anti-inflammatory activity in preclinical models.
• Brassicasterol: A metabolic product of ergosterol with reported effects on bladder epithelial cells. Experiments with rats fed a diet containing 0.1% ergosterol have shown a certain bladder carcinogenesis-preventing effect.
• 5,6-dehydroergosterol: Ergosterol, 5,6-dehydroergosterol, and ergosterol peroxide have been found to exhibit significant in vitro anticancer activities.

5.4 Signaling Pathways and Molecular Mechanisms

Current evidence links ergosterol-related interventions to changes in signaling pathways such as PI3K/Akt, NF-κB, and Wnt/β-catenin, although direct target-engagement evidence remains limited for many disease models.

Ergosterol exhibits anti-inflammatory activity via modulation of the JAK–STAT pathway and suppression of iNOS and COX-2. It also provides neuroprotection by inhibiting TLR4/NF-κB signalling. The anti-inflammatory activity of ergosterol has also been attributed to the suppression of the proinflammatory cytokines including TNF-α, IL-6 and IL-1β.

Mechanistically, ergosterol in its pure or derivative forms has been reported to induce caspase-mediated intrinsic apoptosis, arrest cell cycle, and inhibit migration and invasion of cancer cells while regulating several signalling pathways including the STAT3 and the IGFR/IRS-1/2-MEK-ras-ERK1/2 pathways.

Due to its structural similarity to cholesterol, ergosterol can compete for incorporation into dietary mixed micelles, reduce cholesterol uptake, and promote fecal cholesterol excretion. At the hepatic and systemic levels, ergosterol has been reported to alter cholesterol metabolism-related readouts, including SREBP-2, LDL-R, HMG-CoR, CYP7A1, and LXR-α in high-cholesterol diet-fed rats.

Ergosterol's biosynthesis involves a complex enzymatic pathway that diverges from the cholesterol (C27 sterol) biosynthesis pathway in mammals, making it an ideal pharmacological target with the potential to disrupt fungal viability without affecting human cells. Recent research has expanded our understanding of ergosterol's role beyond membrane structure, highlighting its function as a molecular rheostat that controls fungal virulence, drug resistance, and immune evasion.

5.5 Immunomodulatory and Plant-Interaction Properties

Ergosterol and other sterols might also participate in interkingdom interactions. In plants, ergosterol represents a microbe-associated molecular pattern recognized as an immunologically active "non-self-antigen." Glycosylated sterols have been linked to immunological protection of the host in an animal model of fungal disease.

6. Scientific Evidence by Area of Use

6.1 Vitamin D₂ Production and Bone Health

Although natural mushrooms often contain very little vitamin D₂, as many are grown in the dark, they are rich in ergosterol, a precursor to vitamin D₂. The conversion of ergosterol to vitamin D₂ in mushrooms upon UV exposure has been extensively documented. White button mushrooms, brown portobello mushrooms, shiitake mushrooms, and oyster mushrooms are some types of mushrooms known to show a vitamin D₂ response when exposed to UV light; with sufficient duration and exposure, the level of vitamin D₂ in these and other mushroom species can reach or exceed 400 IU/85 g of fresh mushrooms, equating to 100% of the current recommended Daily Value for vitamin D in the United States.

The conversion of ergosterol to vitamin D₂ at ambient temperature almost reached completion within 10 minutes under UV-B exposure, resulting in vitamin D₂ concentrations of 365 µg per gram of dry matter in one study using Pleurotus sapidus mycelium. Under optimal UV irradiation conditions, vitamin D₂ increased from undetectable to 40.59 ± 1.16 µg/g (dry weight) in dry shiitake mushroom powder and to 677.28 ± 40.42 µg/g (dry weight) in oyster mushroom powder in ethanol suspension.

Evidence strength: The photoconversion of ergosterol to vitamin D₂ is well-established chemistry. The nutritional role of ergosterol-derived vitamin D₂ in mushrooms as a dietary vitamin D source is supported by multiple controlled food-science studies. Human clinical evidence specifically isolating ergosterol's role in bone health (independent of the vitamin D₂ it produces) is absent.

6.2 Anticancer Activity

Ergosterol has been reported to exhibit potent anticancer activity. The body of evidence here is predominantly preclinical (in vitro cell culture and animal models).

Ergosterol had long been recognized as an important bioactive compound isolated from medicinal fungi. Yazawa and co-workers showed that ergosterol, isolated from Polyporus, provides significant protection against the promotion of bladder tumor in rats induced by many types of environmental promoters. Takaku et al. reported that ergosterol isolated from Agaricus blazei directly inhibited angiogenesis induced by solid tumors, using a neovascularization model induced by Lewis lung carcinoma cell-packed chambers and Matrigel.

Studies demonstrate that ergosterol exhibits anticancer effects by inducing apoptosis and modulating metabolic pathways in breast cancer cells. In a study on the medicinal mushroom Amauroderma rude, purified ergosterol was shown to inhibit cancer growth both in vitro and in vivo by upregulating multiple tumor suppressors. In the Boyden chamber migration assay, the purified ergosterol exerted a significant inhibitory effect on cancer cell migration at the concentration of 10 µg/mL.

In disease models, parent ergosterol has been associated with glucose and lipid metabolism, cholesterol regulation, anti-inflammatory activity, antioxidant effects, renal protection, pulmonary protection, and selected anticancer effects.

Although these reports demonstrated the potential therapeutic benefits of ergosterol and its derivatives against cancer and inflammatory diseases, further in vivo mechanistic studies to evaluate their bioavailability and potential toxicity are warranted to lay the foundation for future clinical trials.

Evidence strength: Preliminary and preclinical only. There are no registered or published human clinical trials evaluating ergosterol as a standalone anticancer agent. All current anticancer evidence derives from cell-line (in vitro) and animal model (in vivo) studies. These findings, while mechanistically interesting, cannot be extrapolated to clinical efficacy in humans without further investigation.

6.3 Anti-Inflammatory Activity

Ergosterol inhibits the aggregation of FcεRI, which is the first step in mast cell activation, and reduces IL-4 and TNF-α mRNA expression in IgE-sensitized RBL-2H3 basophilic leukemia cells. Moreover, ergosterol significantly inhibits the activities of β-hexosaminidase and mucosal-type murine bone-marrow-derived mast cells. Similarly, both the ergosterol-rich extract of Grifola frondosa and pure ergosterol inhibit histamine release in air pouch-type allergic inflammation and reduce vascular permeability and edema in mice.

Ergosterol is a component of fungal cell membranes that has physiological functions and applications in drugs, such as anti-inflammatory, anti-tumor, anti-fungal, and other immunosuppressive activities.

Evidence strength: Preclinical. Anti-inflammatory mechanisms have been characterized in cell culture and animal models. No human randomized controlled trials (RCTs) have evaluated ergosterol specifically for inflammatory conditions. Evidence is mechanistically promising but remains at an early translational stage.

6.4 Cholesterol-Lowering Effects

Ergosterol, the predominant sterol in fungal cell membranes and a dietary component of edible mushrooms, has been reported to exhibit antioxidant, anti-inflammatory, and cholesterol-lowering properties. The proposed mechanism involves competition with cholesterol for intestinal absorption. Due to its structural similarity to cholesterol, ergosterol can compete for incorporation into dietary mixed micelles, reduce cholesterol uptake, and promote fecal cholesterol excretion.

An in silico study modeled ergosterol as a natural modulator of intestinal cholesterol absorption via NPC1L1 (Niemann-Pick C1-Like 1), the key cholesterol transporter targeted by the drug ezetimibe. Molecular dynamics simulation results reinforced the stability and compaction patterns of the NPC1L1-ligand complexes obtained from docking studies, with RMSD and RMSF analysis exhibiting moderate deviation and minor fluctuation of the NPC1L1-ergosterol complex in comparison with the NPC1L1-ezetimibe complex.

Evidence strength: Preliminary; largely in silico and animal-model data. While the mechanistic rationale for cholesterol-lowering effects is plausible given structural similarities with other phytosterols, clinical human trial data specific to ergosterol as an isolated cholesterol-lowering agent are lacking.

6.5 Uric Acid Regulation and Gout

For uric acid regulation, ergosterol-related interventions have been reported to reduce uric acid levels in hyperuricemia or gouty nephropathy models. Anticancer, antidiabetic, antimicrobial, and anti-platelet aggregation properties have been reported alongside anti-inflammatory activity and neuroprotective effects.

Evidence strength: Preclinical only. Evidence for uric acid modulation derives from animal models of hyperuricemia and gouty nephropathy. No human studies have examined ergosterol as a uricosuric or xanthine oxidase-inhibiting agent.

6.6 Antidiabetic Effects and Renal Protection in Diabetic Nephropathy

Ergosterol from Pleurotus ostreatus shows antidiabetic activity, and its derivatives inhibit Helicobacter pylori and Aspergillus flavus. Previous preclinical studies have confirmed that ergosterol can ameliorate diabetic nephropathy by suppressing the proliferation of mesangial cells and the accumulation of extracellular matrix (ECM). To address its poor oral bioavailability in this context, ergosterol-loaded nanostructured lipid carriers (ERG-NLCs) have been developed. ERG-NLCs were prepared using glyceryl monostearate by hot emulsification–ultrasonication and characterized by dynamic light scattering, transmission electron microscopy, and differential scanning calorimetry.

Evidence strength: Preclinical only. Anti-diabetic and nephroprotective findings come exclusively from cell and animal models. No human clinical trials have examined ergosterol for diabetes management or kidney protection.

6.7 Antioxidant Activity

Ergosterol has been reported to exhibit antioxidant properties alongside its anti-inflammatory and cholesterol-lowering effects. Preclinical studies have demonstrated that ergosterol activates the Nrf2/HO-1 pathway (a key cellular antioxidant defense axis), reduces reactive oxygen species (ROS) generation, and modulates markers such as superoxide dismutase (SOD) and malondialdehyde (MDA) in oxidative stress models.

Evidence strength: Preclinical only. Antioxidant evidence is drawn exclusively from in vitro assays (e.g., DPPH radical scavenging) and animal models. No human intervention trials have assessed ergosterol's antioxidant effects as a primary endpoint.

6.8 Neuroprotection

Ergosterol provides neuroprotection by inhibiting TLR4/NF-κB signalling. Lung injury, neuroprotection, gut microbiota modulation, and other areas represent fields where ergosterol evidence is particularly sparse and early-stage. Emerging evidence also suggests its role in ameliorating hepatic steatosis, underscoring its therapeutic potential in inflammatory, metabolic, and infectious diseases.

Evidence strength: Highly preliminary; in vitro and limited animal data only.

6.9 Ergosterol as an Antifungal Drug Target (Pharmacological, Not Supplemental)

A major, well-established role for ergosterol in medicine is not as a supplement to be taken but as the molecular target of antifungal drugs. Because ergosterol is present in cell membranes of fungi, yet absent in those of animals, it is a useful target for antifungal drugs.

The general mechanism by which azole antifungal drugs work is by inhibiting lanosterol 14-alpha-demethylase, which converts lanosterol to ergosterol in fungal cellular membranes. The inability to produce ergosterol increases the membrane's permeability, which results in cell lysis and death. Azoles block the ergosterol biosynthesis pathway via inhibition of 14-α sterol demethylase (Cyp51/Erg11), a key enzyme that removes the methyl group at position C-14 of precursor sterols; inhibition of ergosterol synthesis at this biochemical level results in toxic sterol accumulation and cell death.

These medications encompass miconazole, ketoconazole, fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole, and oteseconazole. Polyene antifungals such as amphotericin B work by a complementary mechanism: they bind directly to ergosterol in the fungal membrane, forming pores that disrupt membrane integrity.

Emergence of resistance to existing antifungals is a current problem, and several secondary resistance mechanisms have been described in Aspergillus fumigatus clinical isolates. A full understanding of ergosterol biosynthetic control therefore appears to be essential for improvement of antifungal efficacy and to prevent antifungal resistance.

7. Body Systems and Health Areas

In disease models, parent ergosterol has been associated with glucose and lipid metabolism, cholesterol regulation, anti-inflammatory activity, antioxidant effects, renal protection, pulmonary protection, and selected anticancer effects. The following organ systems and health domains have received investigation:

• Skeletal system / calcium-phosphorus metabolism: Via conversion to vitamin D₂ (ergocalciferol), ergosterol is ultimately linked to calcium absorption, bone mineralization, and rickets/osteoporosis prevention.
• Cardiovascular system: Cholesterol-lowering potential through competition with intestinal cholesterol uptake.
• Immune system: Mast cell stabilization, reduction of allergic mediators, modulation of cytokines including TNF-α, IL-6, and IL-1β.
• Oncology: Induction of apoptosis, cell cycle arrest, inhibition of angiogenesis, and anti-metastatic effects in preclinical cancer models.
• Renal system: Amelioration of diabetic nephropathy markers in animal models.
• Metabolic system: Antidiabetic activity; uric acid reduction in hyperuricemia models.
• Nervous system: TLR4/NF-κB-mediated neuroprotection in early-stage models.
• Hepatic system: Emerging evidence for effects on hepatic steatosis.
• Infectious disease (antifungal context): As the primary target of azole and polyene antifungals, ergosterol is central to fungal pathophysiology.

8. Pharmacokinetics

Pharmacokinetic limitations are central to evaluating the translational potential of ergosterol. Although ergosterol and its derivatives have been associated with diverse biological activities, it remains uncertain whether many of these effects can be achieved at pharmacologically relevant systemic or tissue exposure levels. Free ergosterol exhibits limited oral bioavailability, largely because of its low aqueous solubility, limited micellar bioaccessibility, incomplete intestinal absorption, metabolic conversion, and fecal elimination.

In the rats orally administered ergosterol for 36 hours, the area under the plasma drug concentration-time curve (AUC₀–₃₆) was 22.29 ± 5.08 µg·h/mL, the half-life was 5.90 ± 1.41 h, the maximum observed concentration (Cmax) was 2.27 ± 0.19 µg/mL, and the time to Cmax was 8.00 ± 1.18 h. Approximately 62.5% of the administered ergosterol was excreted in feces, whereas 3.2% was eliminated in urine.

The oral bioavailability of ergosterol is not known because intravenous injection of ergosterol has not been carried out in a pharmacokinetic study for the calculation of bioavailability. However, the oral bioavailability is expected to be low, as reflected from the long time required to achieve Cmax.

Although ergosterol has shown potential as a drug molecule for the treatment of various diseases, a major hindrance to its therapeutic application is its low oral bioavailability and poor aqueous solubility. Due to these issues, the drug requires a longer duration to reach its highest concentration in the blood after consumption.

To overcome these barriers, delivery systems in ergosterol-related research mainly serve to enhance ergosterol exposure by improving solubilization, protecting the molecule from degradation during gastrointestinal transit, and ultimately increasing oral absorption and systemic bioavailability. The oral bioavailability of ergosterol can be increased after encapsulation in PLGA nanoparticles.

An in silico ADMET analysis produced a more optimistic picture: pharmacokinetic and toxicity analysis using pkCSM demonstrated that ergosterol adheres to Lipinski's rule of five and is characterized by high oral bioavailability, favourable distribution, higher intestinal absorption, and minimal toxicity risk. However, it must be emphasized that in silico predictions and in vitro/animal pharmacokinetic data do not reliably predict human outcomes, and formal human pharmacokinetic studies on ergosterol as an isolated supplement are not available in the published literature.

9. Dosage Forms and Dosages Reported in Studies

There is no established human clinical dosage for ergosterol as a standalone supplement. The following dosages appear in the preclinical research literature:

• Animal dietary studies (cholesterol/bladder cancer prevention): Experiments with rats fed a diet containing 0.1% ergosterol have shown a certain bladder carcinogenesis-preventing effect.
• In vitro anticancer studies: At the concentration of 10 µg/mL, purified ergosterol exerted a significant inhibitory effect on cancer cell migration in the Boyden chamber migration assay.
• Nanostructured lipid carrier studies (diabetic nephropathy, rat model): ERG-NLCs were prepared using glyceryl monostearate and decanoyl/octanoyl-glycerides by hot emulsification–ultrasonication but specific dosages in mg/kg used in animal treatment arms were not retrievable from the available abstract data.
• Mushroom-derived vitamin D₂ (human nutritional context): With sufficient UV exposure, the level of vitamin D₂ in mushroom species can reach or exceed 400 IU/85 g of fresh mushrooms, equating to 100% of the current recommended Daily Value for vitamin D in the United States.

Because no Phase I, II, or III human clinical trials for ergosterol as a dietary supplement have been published, there is no evidence-based recommended human dose for the isolated compound.

10. Safety Considerations and Interactions

10.1 Predicted Toxicological Profile of Ergosterol

According to Lipinski's rule, ergosterol exhibited drug-like properties. Additionally, ergosterol did not cause hepatotoxicity or skin allergy in predictive in silico models, and its predicted median lethal dose in rats was 2.05 mol/kg. Moreover, without the functional groups that confer carcinogenicity or mutagenicity as indicated by the Benigni–Bossa rule, ergosterol was assumed to be non-carcinogenic and non-mutagenic.

The maximum tolerated dose (MTD) for ergosterol suggests slightly lower tolerability than ezetimibe, and oral rat acute toxicity (LD50) values indicate that ezetimibe is less acutely toxic than ergosterol. However, administration of ergosterol at lower doses may alleviate potential toxicity concerns.

10.2 Vitamin D Toxicity Risk (Indirect)

Because ergosterol is the precursor of vitamin D₂, the conversion of dietary ergosterol to ergocalciferol is a relevant safety consideration when consuming large quantities of UV-irradiated mushrooms or purified preparations. Toxicity from vitamin D supplementation has been observed only when there is consistent intake far in excess of 10,000 IU/day. At dietary mushroom intake levels, this is not a practical concern, but concentrated ergosterol supplements intended to produce large amounts of vitamin D₂ would carry the same risk profile as high-dose vitamin D₂ supplementation.

10.3 Drug Interactions — Azole Antifungal Context

Although ergosterol itself is not the drug, understanding interactions with the ergosterol pathway is clinically important for patients taking antifungal medications. All azole antifungals are involved in drug-drug interactions via cytochrome P450 enzyme metabolism. Fluconazole strongly inhibits CYP2C19 and moderately inhibits CYP2C9 and CYP3A4.

In contrast, ergosterol was predicted not to be a substrate of CYP2D6, and was predicted not to inhibit CYP1A2, CYP2C19, CYP2C9, CYP2D6, or CYP3A4 in the in silico analysis — suggesting a low intrinsic drug-interaction potential for ergosterol itself as a supplement, though human data confirming this are absent.

10.4 Limitations of Current Safety Data

Overall, disease-oriented evidence for ergosterol-related compounds is broad but uneven. Pharmacokinetic limitations are central to evaluating the translational potential of ergosterol. It remains uncertain whether many biological effects can be achieved at pharmacologically relevant systemic or tissue exposure levels. All safety characterization of purified ergosterol in living organisms comes from rat and in silico studies; there are no systematic human safety or toxicology trials for ergosterol as an isolated supplement. Individuals with conditions that affect sterol or lipid metabolism, or those on medications that interact with the cytochrome P450 system, should be considered as potential special populations requiring evaluation, though no specific interaction data in humans currently exist for ergosterol itself.

11. Current Research Directions

Current evidence links ergosterol-related interventions to changes in signaling pathways such as PI3K/Akt, NF-κB, and Wnt/β-catenin, although direct target-engagement evidence remains limited for many disease models. Ongoing research directions include:

• Advanced drug delivery: A range of carriers — including liposomes, nanoparticles, microemulsions, micelles, and ferritin cages — has been developed to increase the effective concentration of ergosterol at target sites.
• Structural modification: Structural modifications of ergosterol and use of effective drug delivery systems are being explored to enhance overall therapeutic performance.
• Ergosterol peroxide derivatives: Ergosterol peroxide represents a potential drug lead compound for the versatile interest of research on steroidal anticancer agents.
• Antifungal resistance: Ergosterol homeostasis represents a promising target for polypharmacological strategies that aim to disrupt multiple aspects of fungal pathogenicity simultaneously.
• Metabolic engineering: Recent advances in synthetic biology have established Saccharomyces cerevisiae as a robust microbial chassis for sterol biosynthesis; through strategic integration of heterologous pathways and systematic enhancement of metabolic flux, this eukaryotic platform has enabled de novo synthesis of diverse high-value steroids.

References

• Ergosterol: Biological Activities, Mechanistic Evidence, Pharmacokinetic Barriers, and Delivery Strategies — MDPI International Journal of Molecular Sciences (2026)
• Potential Beneficial Effects and Pharmacological Properties of Ergosterol, a Common Bioactive Compound in Edible Mushrooms — PMC / Foods (2023)
• Ergosterol as a Natural Modulator of Intestinal Cholesterol Absorption via NPC1L1: An In Silico Insight into Hypercholesterolemia — PMC (2025)
• Characterization of the Ergosterol Biosynthesis Pathway in Ceratocystidaceae — PMC (2021)
• Structure and Biological Activity of Ergostane-Type Steroids from Fungi — PMC (2022)
• The Multifunctional Fungal Ergosterol — PMC / mBio (2018)
• Effect Mechanism of Ergosterol from Leucocalocybe mongolica in Breast Cancer Cells — PMC (2024)
• Ergosterol Purified from Medicinal Mushroom Amauroderma rude Inhibits Cancer Growth In Vitro and In Vivo — Oncotarget (2015)
• UV-Induced Conversion During Drying of Ergosterol to Vitamin D in Various Mushrooms — PMC (2020)
• Vitamin D2, Ergosterol, and Vitamin B2 Content in Commercially Dried Mushrooms in China — PubMed (2016)
• Ultraviolet Irradiation Increased Vitamin D2 and Decreased Ergosterol in Shiitake and Oyster Mushroom Powder — ACS Omega (2020)
• Conversion of Ergosterol into Vitamin D2 and Other Photoisomers in Agaricus bisporus Under UV-C Irradiation — ScienceDirect (2022)
• Enrichment of Vitamin D2 in Mycelium from Submerged Cultures of Pleurotus sapidus — PMC (2018)
• Antifungal Ergosterol Synthesis Inhibitors — StatPearls, NCBI Bookshelf (2024)
• Ergosterol Biosynthesis in Aspergillus fumigatus: Relevance as Antifungal Target and Role in Drug Resistance — PMC (2013)
• Regulation of Ergosterol Biosynthesis in Pathogenic Fungi: Opportunities for Therapeutic Development — PMC (2025)
• Antifungal Agents: Mode of Action, Mechanisms of Resistance — PMC / Clinical Microbiology Reviews (2001)
• Enhancement and Mechanism of Ergosterol Biosynthesis in Athelia termitophila by Methyl Jasmonate — PMC (2025)
• Preparation of Ergosterol-Loaded Nanostructured Lipid Carriers for Enhancing Oral Bioavailability and Antidiabetic Nephropathy Effects — AAPS PharmSciTech (2020)
• Molecular Targets of Ergosterol and Its Derivatives in Cancer Therapy: Recent Trends and Strategies to Improve Bioavailability — ScienceDirect (2025)
• Early Preclinical Studies of Ergosterol Peroxide and Biological Evaluation of Its Derivatives — ACS Omega (2024)
• Phylogenetic Distribution of Fungal Sterols — PLOS ONE (2010)
• Edible Mushrooms: Improving Human Health and Promoting Quality Life — PMC (2015)
• The Medicinal Values of Culinary-Medicinal Royal Sun Mushroom (Agaricus blazei Murrill) — PMC (2013)
• Ganoderma lucidum (Lingzhi or Reishi) — Herbal Medicine, NCBI Bookshelf
• Agaricus subrufescens: A Review — PMC (2013)
• Ergosterol — Taylor & Francis Knowledge, Clinical Nutrition Reference